An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK3277510A and GSK3277509A Administered in Adults 18 to 60 Years of Age
Status: Withdrawn prior to enrolment
Phase of Trial: Phase I
Latest Information Update: 22 Jun 2016
Price : $35 *
At a glance
- Drugs GSK 3277509A (Primary) ; GSK 3277510A (Primary)
- Indications Influenza A virus H7N9 subtype
- Focus Adverse reactions; Pharmacodynamics
- Sponsors GlaxoSmithKline
- 16 Jun 2016 Status changed from not yet recruiting to withdrawn prior to enrolment due to scientifically legitimate reasons not related to safety or efficacy of the vaccine.
- 31 Jul 2014 Planned End Date changed from 1 Dec 2015 to 1 Feb 2017 as reported by ClinicalTrials.gov record.
- 31 Jul 2014 Planned primary completion date changed from 1 Dec 2014 to 1 Feb 2016 as reported by ClinicalTrials.gov record.